These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 34485162)

  • 1. Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives.
    Roccuzzo G; Giordano S; Fava P; Pileri A; Guglielmo A; Tonella L; Sanlorenzo M; Ribero S; Fierro MT; Quaglino P
    Front Oncol; 2021; 11():733770. PubMed ID: 34485162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab in two cases of refractory mycosis fungoides erythroderma.
    Chmielowska E
    Cent Eur J Immunol; 2021; 46(4):535-538. PubMed ID: 35125955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycosis Fungoides and Sézary Syndrome: Microenvironment and Cancer Progression.
    Dobos G; Lazaridou I; de Masson A
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
    Whittaker SJ; Foss FM
    Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments.
    Sivanand A; Surmanowicz P; Alhusayen R; Hull P; Litvinov IV; Zhou Y; Gniadecki R
    J Cutan Med Surg; 2019; 23(5):537-544. PubMed ID: 31353944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-mycosis fungoides cutaneous T-cell lymphoma: reclassification according to the WHO-EORTC classification.
    Weaver J; Mahindra AK; Pohlman B; Jin T; Hsi ED
    J Cutan Pathol; 2010 May; 37(5):516-24. PubMed ID: 20132421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma.
    Pelcovits A; Ollila TA; Olszewski AJ
    Cancer Manag Res; 2023; 15():989-998. PubMed ID: 37700809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
    Van-de-Velde V; Zhou Y
    J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario.
    Sanches JA; Cury-Martins J; Abreu RM; Miyashiro D; Pereira J
    An Bras Dermatol; 2021; 96(4):458-471. PubMed ID: 34053802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
    Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
    Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.
    Querfeld C; Zain J; Rosen ST
    Cancer Treat Res; 2019; 176():225-248. PubMed ID: 30596221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous Lymphomas - Part I: Mycosis Fungoides, Sézary Syndrome, and CD30
    Pujol RM; Gallardo F
    Actas Dermosifiliogr (Engl Ed); 2021 Jan; 112(1):14-23. PubMed ID: 32896500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous T-cell lymphomas: a review with emphasis on new treatment approaches.
    Querfeld C; Rosen ST; Kuzel TM; Guitart J
    Semin Cutan Med Surg; 2003 Sep; 22(3):150-61. PubMed ID: 14649582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that an identical T cell clone in skin and peripheral blood lymphocytes is an independent prognostic factor in primary cutaneous T cell lymphomas.
    Beylot-Barry M; Sibaud V; Thiebaut R; Vergier B; Beylot C; Delaunay M; Chene G; Dubus P; Merlio JP
    J Invest Dermatol; 2001 Oct; 117(4):920-6. PubMed ID: 11676833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in understanding and managing cutaneous T-cell lymphomas.
    Brunner PM; Jonak C; Knobler R
    F1000Res; 2020; 9():. PubMed ID: 32419924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous T cell lymphomas: mycosis fungoides, Sezary syndrome and HTLV-I-associated adult T cell leukemia (ATL) in Mali, West Africa: a clinical, pathological and immunovirological study of 14 cases and a review of the African ATL cases.
    Fouchard N; Mahe A; Huerre M; Fraitag S; Valensi F; Macintyre E; Sanou F; de The G; Gessain A
    Leukemia; 1998 Apr; 12(4):578-85. PubMed ID: 9557617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome.
    Oka T; Miyagaki T
    Front Med (Lausanne); 2019; 6():116. PubMed ID: 31192214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas.
    Dumont M; Peffault de Latour R; Ram-Wolff C; Bagot M; de Masson A
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33023002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.